RE: Still No TR-1Today 08:10
After last weeks (transformative?) RNS I'm surprised folks can still buy shares here sub 3p (mcap £10M!!). It won't last.....
RNS: Commenting, Professor Dawn Coverley, Founder and CSO of Cizzle Biotechnology, said:
"After years of work by dedicated scientists here in York, seeing the CIZ1B test finally move from bench to clinic is wonderful. We hope that its many practical advantages over other methods, including low cost and the need for very small quantities of blood, will mean that its use can be expanded into rapid and regular screening for lung cancer."
Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:
"CLIA accreditation for our CIZ1B biomarker test is a major milestone for the Company. This was rightly a rigorous process to demonstrate the CIZ1B test is reliable and accurate and can now be used in licensed clinical laboratories as an important tool to help detect lung cancer early and save lives. As with any major challenge, it requires expert and determined collaboration to achieve significant breakthroughs in the fight against cancer. The outstanding efforts from our team at the University of York along with BIO and the clinical laboratory team at Omni are testament to making this potentially lifesaving test a reality."